b raf kinase assay  (BPS Bioscience)

Journal: Molecular Medicine Reports

Article Title: RUVBL1 and CRAF promote periodontal ligament stem cell osteogenic differentiation via the MEK/ERK signaling cascade

doi: 10.3892/mmr.2026.13881

Figure Lengend Snippet: Overexpression of CRAF activates the RAF/MEK/ERK signaling pathway. Reverse transcription-quantitative PCR was used to analyze the mRNA expression of (A) ARAF, (B) BRAF, (C) CRAF, (D) MEK1, (E) MEK2, (F) ERK1and (G) ERK2. Western blotting was used to analyze the protein levels of (H) ARAF, (I) BRAF, (J) CRAF, (K) MEK1/2, (L) p-MEK1/2, (M) p-MEK1/2 to MEK1/2, (N) ERK1/2, (O) p-ERK1/2 and (P) p-ERK1/2 to ERK1/2. *P<0.05, **P<0.01 and ***P<0.001. p-, phosphorylated; OE, overexpression; NC, negative control; sh, short hairpin; ns, not significant; ARAF, A-Raf proto-oncogene serine/threonine-protein kinase; BRAF, B-Raf proto-oncogene serine/threonine-protein kinase; CRAF, C-Raf proto-oncogene serine/threonine-protein kinase.

Article Snippet: The antibodies were as follows: GAPDH (1:1,000; cat. no. P30008M; Abmart Pharmaceutical Technology Co., Ltd.), A-Raf proto-oncogene serine/threonine-protein kinase (ARAF) (cat. no. bs-2251R), CRAF (cat. no. bs-23170R), MEK1/2 (cat. no. bs-1041R), phosphorylated (p)-MEK1/2 (cat. no. bs-3270R), ERK1/2 (cat. no. bsm-33232M), p-ERK1/2 (cat. no. bs-3016R; all BIOSS), RUVBL1 (cat. no. 74775; Cell Signaling Technology, Inc.), ERK1/2 (all 1:500; cat. no. bsm-33232M; BIOSS), B-Raf proto-oncogene serine/threonine-protein kinase (BRAF) (1:2,000; cat. no. ab33899; Abcam) and HRP-conjugated universal secondary antibody [cat. nos.

Techniques: Over Expression, Reverse Transcription, Real-time Polymerase Chain Reaction, Expressing, Western Blot, Negative Control

Journal: Molecular Medicine Reports

Article Title: RUVBL1 and CRAF promote periodontal ligament stem cell osteogenic differentiation via the MEK/ERK signaling cascade

doi: 10.3892/mmr.2026.13881

Figure Lengend Snippet: Overexpression of RUVBL1 activates the MEK/ERK signaling pathway. Reverse transcription-quantitative PCR was used to analyze the mRNA expression of (A) ARAF, (B) BRAF, (C) CRAF, (D) MEK1, (E) MEK2, (F) ERK1 and (G) ERK2. Western blotting was used to analyze protein levels of (H) ARAF, (I) BRAF, (J) CRAF, (K) MEK1/2, (L) p-MEK1/2, (M) p-MEK1/2 to MEK1/2, (N) ERK1/2, (O) p-ERK1/2 and (P) p-ERK1/2 to ERK1/2. *P<0.05, **P<0.01 and ***P<0.001. RUVBL1, RuvB-like AAA ATPase-1; p-, phosphorylated; OE, overexpression; NC, negative control; sh, short hairpin; ns, not significant; ARAF, A-Raf proto-oncogene serine/threonine-protein kinase; BRAF, B-Raf proto-oncogene serine/threonine-protein kinase; CRAF, C-Raf proto-oncogene serine/threonine-protein kinase.

Article Snippet: The antibodies were as follows: GAPDH (1:1,000; cat. no. P30008M; Abmart Pharmaceutical Technology Co., Ltd.), A-Raf proto-oncogene serine/threonine-protein kinase (ARAF) (cat. no. bs-2251R), CRAF (cat. no. bs-23170R), MEK1/2 (cat. no. bs-1041R), phosphorylated (p)-MEK1/2 (cat. no. bs-3270R), ERK1/2 (cat. no. bsm-33232M), p-ERK1/2 (cat. no. bs-3016R; all BIOSS), RUVBL1 (cat. no. 74775; Cell Signaling Technology, Inc.), ERK1/2 (all 1:500; cat. no. bsm-33232M; BIOSS), B-Raf proto-oncogene serine/threonine-protein kinase (BRAF) (1:2,000; cat. no. ab33899; Abcam) and HRP-conjugated universal secondary antibody [cat. nos.

Techniques: Over Expression, Reverse Transcription, Real-time Polymerase Chain Reaction, Expressing, Western Blot, Negative Control

Journal: Molecular Medicine Reports

Article Title: RUVBL1 and CRAF promote periodontal ligament stem cell osteogenic differentiation via the MEK/ERK signaling cascade

doi: 10.3892/mmr.2026.13881

Figure Lengend Snippet: ODN MT01 promotes osteogenic differentiation of PDLSCs. (A) PDLSC proliferation and (B) ALP staining following treatment with varying concentrations of ODN MT01. (C) Osteogenic differentiation and (D) mineralization after the addition of ODN MT01 and osteogenic inducers. ALP staining was used to assess the effect of (E) CRAF and (F) RUVBL1 on osteogenic differentiation of PDLSCs following the addition of ODN MT01 and osteogenic inducers. Alizarin Red staining was used to assess the effect of (G) CRAF and (H) RUVBL1 on the degree of mineralization of PDLSCs following the addition of ODN MT01 and osteogenic inducers. *P<0.05 and ***P<0.001. ODN, oligodeoxynucleotide; PDLSC, periodontal ligament stem cell; ALP, alkaline phosphatase, RUVBL1, RuvB-like AAA ATPase-1; NC, negative control; OE, overexpression; sh, short hairpin; ns, not significant; CRAF, C-Raf proto-oncogene serine/threonine-protein kinase; OI, osteogenic induction; OM, ODN MT01.

Article Snippet: The antibodies were as follows: GAPDH (1:1,000; cat. no. P30008M; Abmart Pharmaceutical Technology Co., Ltd.), A-Raf proto-oncogene serine/threonine-protein kinase (ARAF) (cat. no. bs-2251R), CRAF (cat. no. bs-23170R), MEK1/2 (cat. no. bs-1041R), phosphorylated (p)-MEK1/2 (cat. no. bs-3270R), ERK1/2 (cat. no. bsm-33232M), p-ERK1/2 (cat. no. bs-3016R; all BIOSS), RUVBL1 (cat. no. 74775; Cell Signaling Technology, Inc.), ERK1/2 (all 1:500; cat. no. bsm-33232M; BIOSS), B-Raf proto-oncogene serine/threonine-protein kinase (BRAF) (1:2,000; cat. no. ab33899; Abcam) and HRP-conjugated universal secondary antibody [cat. nos.

Techniques: Staining, Negative Control, Over Expression

Journal: Scientific Reports

Article Title: Second-generation BRAF inhibitor Encorafenib resistance is regulated by NCOA4-mediated iron trafficking in the drug-resistant malignant melanoma cells

doi: 10.1038/s41598-025-86874-3

Figure Lengend Snippet: Characterization of Encorafenib resistance and investigation of resistance-related molecular mechanisms by Western blot and RNA-Seq ( a ) Resistance characterization at the protein levels is shown for the indicated proteins ( n = 3), and in particular, AKT, p-AKT, and ERK levels are observed to increase in A375-R cells. Agilent Bioanalyzer images for the quality of ( b ) RNA samples and ( c ) cDNA libraries for RNA-Seq analysis are indicated ( d ) Transcriptomic analysis results for the group comparisons, including A375-SC vs. A375-RC, A375-SC vs. A375-S10, A375-RC vs. A375-R10, the numbers of genes with common functions are represented in the colorful graphs with the fold changes and p values ​​obtained from the bioinformatics analysis.

Article Snippet: The primer antibodies for Y-box binding protein 1 (YB-1), multidrug resistance 1 (MDR1), AKT serine/threonine kinase (AKT), phospho-AKT serine/threonine kinase (p-AKT), extracellular signal-regulated kinases (ERK), phospho-extracellular signal-regulated kinases (p-ERK), serine/threonine-protein kinase B-Raf (BRAF), and β-Actin were obtained from Cell Signaling Technology (CST) (Danvers, MA USA).

Techniques: Western Blot, RNA Sequencing Assay

Journal: Technology in Cancer Research & Treatment

Article Title: Genetic Profiling of Non-Small Cell Lung Cancer in Moroccan Patients by Targeted Next-Generation Sequencing

doi: 10.1177/15330338241288907

Figure Lengend Snippet: Oncomine Precision Gene List and the Associated Biological Processes and Molecular Functions.

Article Snippet: BRAF*# , Serine/threonine-protein kinase B-raf P15056 , Cell signaling , Kinase, Serine/threonine-protein kinase, Transferase.

Techniques: Full Display Name, Virus, Binding Assay, Activity Assay, Chemotaxis Assay, Transduction

Journal: RSC Advances

Article Title: New pyrazolylindolin-2-one based coumarin derivatives as anti-melanoma agents: design, synthesis, dual BRAF V600E /VEGFR-2 inhibition, and computational studies †

doi: 10.1039/d4ra00157e

Figure Lengend Snippet: (A) Examples of FDA approved anti-melanoma drugs. (B) Dual inhibitors of BRAF/VEGFR-2.

Article Snippet: After drug exposure for 24 h, the media were collected for the measurement of the concentrations of BRAF V600E and VEGFR-2 using the Human BRAF (B-Raf Proto Oncogene Serine/Threonine Protein Kinase) ELISA Kit (Elabscience) and Human VEGFR-2/KDR (vascular endothelial growth factor receptor 2) ELISA Kit (Elabscience), respectively, according to the instructions.

Techniques:

Journal: RSC Advances

Article Title: New pyrazolylindolin-2-one based coumarin derivatives as anti-melanoma agents: design, synthesis, dual BRAF V600E /VEGFR-2 inhibition, and computational studies †

doi: 10.1039/d4ra00157e

Figure Lengend Snippet: In vitro BRAF V600E and VEGFR-2 inhibitory activities

Article Snippet: After drug exposure for 24 h, the media were collected for the measurement of the concentrations of BRAF V600E and VEGFR-2 using the Human BRAF (B-Raf Proto Oncogene Serine/Threonine Protein Kinase) ELISA Kit (Elabscience) and Human VEGFR-2/KDR (vascular endothelial growth factor receptor 2) ELISA Kit (Elabscience), respectively, according to the instructions.

Techniques: In Vitro

Journal: RSC Advances

Article Title: New pyrazolylindolin-2-one based coumarin derivatives as anti-melanoma agents: design, synthesis, dual BRAF V600E /VEGFR-2 inhibition, and computational studies †

doi: 10.1039/d4ra00157e

Figure Lengend Snippet: Docking results against BRAF V600E (PBD = 2FB8 ) and TPSA

Article Snippet: After drug exposure for 24 h, the media were collected for the measurement of the concentrations of BRAF V600E and VEGFR-2 using the Human BRAF (B-Raf Proto Oncogene Serine/Threonine Protein Kinase) ELISA Kit (Elabscience) and Human VEGFR-2/KDR (vascular endothelial growth factor receptor 2) ELISA Kit (Elabscience), respectively, according to the instructions.

Techniques:

Journal: RSC Advances

Article Title: New pyrazolylindolin-2-one based coumarin derivatives as anti-melanoma agents: design, synthesis, dual BRAF V600E /VEGFR-2 inhibition, and computational studies †

doi: 10.1039/d4ra00157e

Figure Lengend Snippet: Docking poses against BRAF V600E (A) SB590885, (B) Sorafenib, and (C) 4j.

Article Snippet: After drug exposure for 24 h, the media were collected for the measurement of the concentrations of BRAF V600E and VEGFR-2 using the Human BRAF (B-Raf Proto Oncogene Serine/Threonine Protein Kinase) ELISA Kit (Elabscience) and Human VEGFR-2/KDR (vascular endothelial growth factor receptor 2) ELISA Kit (Elabscience), respectively, according to the instructions.

Techniques: